{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:54:37Z","timestamp":1793386477354,"version":"4.5.0"},"reference-count":29,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["PCN Reports"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>This study evaluated the long\u2010term safety and efficacy of venlafaxine extended release (ER), which has been administered for 52 weeks in Japanese adult outpatients with generalized anxiety disorder (GAD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this open\u2010label, long\u2010term extension, multicenter study, 135 Japanese patients with GAD were enrolled after completing 10 weeks of treatment with venlafaxine ER or placebo (including tapering) during the preceding placebo\u2010controlled, double\u2010blind study. Venlafaxine ER 75\u2013225\u2009mg\/day was to be administered to all participants for 52 weeks in this study. Primary endpoints were the incidence of adverse events and suicidal ideation\/behavior. Secondary endpoints included scores of the Hamilton Anxiety Rating Scale (HAM\u2010A), Clinical Global Impressions\u2010Severity of Illness (CGI\u2010S), and Clinical Global Impressions\u2010Global Improvement (CGI\u2010I).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Venlafaxine ER was overall well\u2010tolerated. Reported adverse events were in line with those reported in the preceding placebo\u2010controlled, double\u2010blind study. No serious adverse events or deaths were reported, and no tendency of venlafaxine ER to induce suicidal ideation was observed. No new safety findings were identified. A constant and consistent decrease in mean HAM\u2010A total scores was observed (baseline: 15.9; Week 52: 8.0), as evidenced by a more pronounced change from baseline. Similar improvements were also observed in CGI\u2010S and CGI\u2010I scores, suggesting the effectiveness of venlafaxine ER with long\u2010term use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The overall safety profile with long\u2010term use of venlafaxine ER was consistent with the one previously observed, confirming the safety of long\u2010term use of venlafaxine ER in Japanese adult patients with GAD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/pcn5.70371","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T09:07:08Z","timestamp":1783328828000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["An open\u2010label, long\u2010term extension, multicenter study to evaluate the safety and efficacy of venlafaxine extended release in Japanese outpatients with generalized anxiety disorder"],"prefix":"10.1002","volume":"5","author":[{"given":"Tempei","family":"Otsubo","sequence":"first","affiliation":[{"name":"Department of Psychosomatic and Psychiatric Medicine Tokyo Women's Medical University Adachi Medical Center Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry Kyorin University School of Medicine Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Psychiatry Sapporo Hanazono Hospital Sapporo Japan"},{"name":"Department of Psychiatry Tokyo Medical University Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ataru","family":"Inagaki","sequence":"additional","affiliation":[{"name":"Department of Education, College of Education, Psychology and Human Studies\/Health Administration Center Aoyama Gakuin University Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Kikuchi","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry Keio University School of Medicine Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7469-2922","authenticated-orcid":false,"given":"Keisuke","family":"Nomoto","sequence":"additional","affiliation":[{"name":"Medical Affairs Viatris Pharmaceuticals Japan G.K. Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Higa","sequence":"additional","affiliation":[{"name":"Medical Affairs Viatris Pharmaceuticals Japan G.K. Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Asami","sequence":"additional","affiliation":[{"name":"Medical Affairs Viatris Pharmaceuticals Japan G.K. Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Sun","sequence":"additional","affiliation":[{"name":"Biometrics, Data Management and Programming Viatris Inc. Canonsburg Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Marschall","sequence":"additional","affiliation":[{"name":"Global Clinical Sciences Meda Pharma GmbH &amp; Co. KG (a Viatris Company) Bad Homburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425787"},{"issue":"2","key":"e_1_2_12_3_1","first-page":"157","article-title":"Generalized anxiety disorder and panic disorder in adults","volume":"106","author":"DeGeorge KC","year":"2022","journal-title":"Am Fam Physician"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.31887\/DCNS.2017.19.2\/macrocq"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2023.2211767"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-021-03363-3"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S456272"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200923020-00002"},{"key":"#cr-split#-e_1_2_12_10_1.1","unstructured":"National Institute for Health and Care Excellence. Generalised anxiety disorder and panic disorder in adults [updated 2020 Jun 15"},{"key":"#cr-split#-e_1_2_12_10_1.2","unstructured":"cited 2025 Jun 10]. Available from:https:\/\/www.nice.org.uk\/guidance\/cg113"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-14-S1-S1"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.31887\/DCNS.2017.19.2\/bbandelow"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S456276"},{"key":"e_1_2_12_14_1","unstructured":"Effexor\u00ae (venlafaxine) SR capsules package insert. Viatris Pharmaceuticals Japan G.K.; 2015 [revised 2026 Mar] (in Japanese) [cited 2026 Mar 24]. Available from:https:\/\/pins.japic.or.jp\/pdf\/newPINS\/00065954.pdf"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.157.6.968"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.v60n0805"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-9338(03)00046-4"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.179.1.15"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.23.3082"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/pcn.13907"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2011.10111704"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2044-8341.1959.tb00467.x"},{"key":"e_1_2_12_23_1","first-page":"218","volume-title":"ECDEU assessment manual for psychopharmacology, revised","author":"Guy W","year":"1976"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000105"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2007.02849.x"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000028140"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1080\/15622975.2022.2086295"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-021-01324-1"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.31887\/DCNS.2008.10.4\/kkelly"}],"container-title":["Psychiatry and Clinical Neurosciences Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pcn5.70371","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pcn5.70371","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pcn5.70371","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:14:06Z","timestamp":1790676846000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pcn5.70371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1002\/pcn5.70371"],"URL":"https:\/\/doi.org\/10.1002\/pcn5.70371","archive":["Portico"],"relation":{},"ISSN":["2769-2558","2769-2558"],"issn-type":[{"value":"2769-2558","type":"print"},{"value":"2769-2558","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"assertion":[{"value":"2026-01-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70371"}}